Saturday 17 October 2026
Export IFRX’s income statement to Excel — free account
InflaRx N.V.
IFRX Healthcare Biotechnology
In the quarter to June 2026, revenue fell 128.9%, EPS grew 54.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.
1.32
0.12
−8.33%
Follow IFRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(71.66%) | (91.00%) | (84.18%) | (38.71%) | |
| (54.61%) | (71.35%) | (66.39%) | (32.75%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(85.54%) | (111.46%) | (116.36%) | (26.85%) | |
Average Days of Receivables |
4,067.40 | 19,277.01 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.71) | (0.60) | (0.47) | (0.23) | |
Free Cash Flow |
(48.16) | (40.09) | (33.95) | (27.23) | |
Capital Expenditures |
(0.15) | (0.13) | (0.10) | (0.17) | |
| Other line items | |||||
Cash ROIC |
(42.73%) | (39.15%) | (36.52%) | (7.61%) | |
Accounts Receivable Turnover |
0.09 | 0.02 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.49 | 0.89 | 0.00 | 0.00 | |
Inventory Turnover |
0.70 | 0.00 | — | — | |
Average Days of Payables |
680.11 | 271.17 | 0.00 | 0.00 | |
Days of Inventory on Hand |
373.76 | 0.00 | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
14,629.58% | 95,099.67% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
10,521.48% | 66,394.12% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
2,518.77% | 16,433.66% | 0.00% | 0.00% | |
Interest Coverage |
(2,070.53) | (1,297.82) | (907.30) | (650.46) | |
Operating CF/Net income |
1.07 | 0.77 | 0.68 | 0.60 | |
Depreciation/Fixed assets |
1.37 | 1.45 | 1.40 | 1.36 | |
Capex/Depreciation |
(0.30) | (0.28) | (0.23) | (0.41) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.71) | (0.59) | (0.47) | (0.23) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.73 | 4.28 | 0.00 | 0.00 |
Columns are period end dates